1 to 50 employees
Celsion is trying to turn up the heat on cancer. The company is developing a heat-activated cancer therapy in the form of its lead drug ThermoDox. ThermoDox combines a common oncology drug, doxorubicin, with a heat-activated liposome that may help deliver and release the drug more accurately. The drug is being studied as a treatment for liver cancer and breast cancer. Celsion was previously a device maker and developed the Prolieve Thermodilatation system, an FDA-approved device used to treat benign prostatic hyperplasia (prostate enlargement). Celsion sold the product line to Boston Scientific in 2007.